EOFlow Co., Ltd., oo bixisa xalalka gudbinta dawooyinka la gashan karo, ayaa maanta ku dhawaaqday in shirkaddeeda ay iska leedahay Mareykanka, EOFlow Inc. ay saxiixday heshiis lagu dhisayo shirkad wadajir ah oo Mareykanka ah oo ay la leedahay shirkadda UK ee bayoolajiga ee Zihipp Limited, oo wareeg ah. ka baxay Imperial College London.
Samaynta lahaanshaha ee analogues-ka waxay u wanaajisaa dhalitaanka joogtada ah ee maqaarka hoostiisa si ay u oggolaato qiyaasta daawada in lagu habeeyo dheef-shiid kiimikaad bukaan gaar ah, xawaaraha dhimista miisaanka iyada oo laga fogaanayo saameynta xun ee qaadashada xad-dhaafka ah. EOFlow waxay bixin doontaa maalgelinta bilowga ah iyo qalabkeeda EOPatch ee la xidhi karo ee gudbinta dawada halka Zihipp uu bixinayo analoogyada peptide-ka ee iska leh iyo taageerada caafimaad ee SanPlena. Maamulaha aasaasiga ah ee EOFlow, Jesse J. Kim, ayaa la wareegi doona doorka aasaasaha aasaasaha SanPlena halka inta kale ee kooxda fulinta ay soo wareejin doonaan shaqaale sare oo ka socda labada Zihipp iyo EOFlow.
Zihipp waa shirkad biotech ah oo UK ah oo ka soo baxday Imperial College London 2012. Waxaa hogaaminaya Prof. Sir Stephen R. Bloom oo aad loo ixtiraamo iyo koox cilmi baaris heer caalami ah, shirkadu waxay soo saartaa hormoonnada peptide si ay ula dagaallanto heerka sare u kaca ee xanuunka macaanka iyo cayilka. Prof.Sir Stephen R. Bloom waa mid ka mid ah khubarada hormoodka u ah buurnida adduunka, cilmi-baadhistiisuna waxa ay diiradda saartay hormoonnada mindhicirka ee xakameeya rabitaanka cuntada iyo dheef-shiid kiimikaadka. Waxaa si fiican loogu yaqaanaa shakhsi ahaan shakhsi ahaaneed ee abuurista hormoonka ku salaysan sonkorowga iyo suuqa daaweynta buurnaanta. Professor Sir Stephen Bloom waa madaxa Horumarinta Maandooriyaha, Waaxda dheef-shiid kiimikaadka, dheefshiidka & taranka ee Kuliyada Imperial London iyo agaasimaha cilmi baarista North West London Pathology ee Imperial College Healthcare NHS Trust, oo u adeegaya lix cosbitaal oo waaweyn.
Zihipp waxa uu soo saaray dhowr musharrax oo cusub oo peptide-ka ah oo loogu talagalay cayilka iyo NASH (aan-khamriga ahayn Steatohepatitis) daawaynta la mid ah hormoonnada rabitaanka cuntada sida oxyntomodulin iyo peptide YY kuwaas oo lagu caddeeyay tijaabooyin caafimaad. Analoogyadan waxa loo hagaajiyey dhalmo-cutaneed joogto ah oo ka hooseeya-ka-hoosaadka si looga fogaado dhibaatooyinka caadiga ah ee la xidhiidha duritaanka maalin kasta ama toddobaadlaha ah ee wakiilada la midka ah. SanPlena waxay rabta inay ka faa'iidaysato faa'iidooyinka EOFlow ee la xidhi karo, madal daryeelka caafimaadka dhijitaalka ah si loo xaqiijiyo ballan qaadka wakiiladan ee wadista miisaan lumis degdeg ah oo lama filaan ah; ilaa 15% miisaanka qofka 2-3 bilood gudahood.
Sida laga soo xigtay Ururka Caafimaadka Adduunka (WHO) iyo Ururka Caalamiga ah ee Cilmi-baarista Cayilka (IASO), 2016, in ka badan 1.9 bilyan oo qaan-gaar ah, 18 sano ama ka weyn, ayaa ahaa kuwo cayilan oo kuwan, 650 million (34%) waxay ahaayeen kuwo cayilan. Daawaynta hadda ee loo heli karo cayilka waxaa xadiday kharashka, degdegga, waxtarka iyo waaritaanka. Tusaale ahaan, daawaynta daroogada ee jirta miisaanka dhimista waxay qaadan kartaa in ka badan hal sano si loo soo saaro 10-15% miisaan lumis ah oo ay weheliso mararka qaarkood waxyeellooyin daran oo caloosha ah. Qalabka cusub ee SanPlena wuxuu u adeegaa baahida weyn ee aan la daboolin ee xulashooyinka daawaynta cusub iyo kuwa cusub ee dhimista miisaanka.
MAXAA LAGU QAADAYAA MAQAALKAN:
- Kim, will assume the role as the founding CEO of SanPlena while the rest of the executive team will be rounded out by senior staff from both Zihipp and EOFlow.
- has signed an agreement to establish a joint venture in the US with the UK biotech firm Zihipp Limited, a spin out from Imperial College London.
- Proprietary formulation of the analogues optimizes them for continuous subcutaneous delivery thus allowing the drug dosing to be tailored to a particular patient’s metabolism, speeding weight loss while avoiding adverse effects from over-dosing.
